Summer Tucker, DO
Family Medicine · Campbellsville, KYNPI 1659505113
Payments from drug & device makers
Across 111 payments — averaging $14.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$296
- AbbVie$242
- Lilly USA, LLC$225
- Amgen$115
- Takeda Pharmaceuticals U.S.A., Inc.$102
- Pfizer$94
- plus $582 from 19 others
What the payments were for
- Food & beverage$1,64799%
- Education$81%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $296 |
| AbbVie(2 entities) | 14 | $242 |
| Lilly USA, LLC | 18 | $225 |
| Amgen | 7 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $102 |
| Pfizer | 7 | $94 |
| Astellas Pharma US Inc | 4 | $62 |
| Axsome Therapeutics, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| AstraZeneca | 3 | $43 |
| GSK | 3 | $42 |
| Shield Therapeutics Inc | 1 | $41 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Exact Sciences | 1 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Almatica Pharma LLC | 1 | $23 |
| Novartis | 1 | $18 |
| Merck | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
How this compares
$1,656 in reported general payments places this provider in the 65th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 101 | $92,264 |
| EliquisApixaban | 151 | $79,643 |
| VraylarCariprazine Hcl | 42 | $59,458 |
| MounjaroTirzepatide | 61 | $54,439 |
| XareltoRivaroxaban | 96 | $46,383 |
| NuedextaDextromethorphan Hbr/Quinidine | 26 | $38,222 |
| ProliaDenosumab | 20 | $34,398 |
| MyrbetriqMirabegron | 71 | $29,313 |
| ViberziEluxadoline | 18 | $28,666 |
| RybelsusSemaglutide | 16 | $22,321 |
| LinzessLinaclotide | 41 | $21,722 |
| JanuviaSitagliptin Phosphate | 14 | $18,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $18,419 |
| Repatha SureclickEvolocumab | 25 | $18,128 |
| UbrelvyUbrogepant | 12 | $11,937 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viberzi, Linzess, Ubrelvy | $242 | $121,782113 claims |
| Novo NordiskOzempic, Rybelsus | $296 | $114,585117 claims |
| PfizerEliquis, Abrysvo | $94 | $84,795168 claims |
| Lilly USA, LLCMounjaro | $225 | $54,43961 claims |
| Johnson & JohnsonXarelto | $24 | $46,38396 claims |
| AmgenProlia | $115 | $34,39820 claims |
| MerckJanuvia, Belsomra, Dulera | $17 | $33,86454 claims |
| Astellas Pharma US IncMyrbetriq | $62 | $29,31371 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy | $42 | $28,79341 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Dexilant | $102 | $10,62844 claims |
| AstraZenecaSymbicort | $43 | $5,26922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Campbellsville
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.